<DOC>
	<DOCNO>NCT00645294</DOCNO>
	<brief_summary>Open-label study pharmacokinetics adefovir dipivoxil child adolescent infect chronic hepatitis B .</brief_summary>
	<brief_title>Open Label Study Pharmacokinetics Safety Dose Adefovir Dipivoxil Children Adolescents With HBV</brief_title>
	<detailed_description>Children adolescents chronic hepatitis B compensate liver , HBeAg-positive serum HBV DNA positive ( great equal 1 x 100,000 copies/mL Roche Amplicor Monitor PCR ) receive dos adefovir dipivoxil cross-over design . Subjects age 2-11 received two single dos ( 0.14 mg/kg 0.3 mg/kg liquid formulation ) subject 2-17 receive one dose ( 10 mg liquid formulation ) .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<criteria>Males female age 2 17 ( inclusive ) chronic hepatitis B evidence follow : HBsAg positive minimum 6 month HBeAg positive HBV DNA great equal 1 x 100,000 copies/mL screen Children adolescent compensate liver disease ALT level great equal 1.2 upper limit normal ( applicable 7 17yearold child adolescent )</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>Adefovir dipivoxil</keyword>
	<keyword>Children</keyword>
	<keyword>Adolescents</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>